Comparative Pharmacology
Head-to-head clinical analysis: PYOPEN versus TOTACILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PYOPEN versus TOTACILLIN.
PYOPEN vs TOTACILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbenicillin is a bactericidal penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Bactericidal: inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation. Active against gram-positive bacteria and some gram-negative bacteria.
4 g intravenously every 4 hours.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours.
None Documented
None Documented
30-60 minutes in normal renal function; prolonged to 2-4 hours in moderate renal impairment (CrCl 10-30 mL/min) and up to 10 hours in severe renal failure.
Terminal elimination half-life: 1.0-1.5 hours in normal renal function. Extended to 2-6 hours in renal impairment; requires dose adjustment when CrCl <30 mL/min.
Primarily renal (60-90% unchanged via glomerular filtration and tubular secretion); small amounts biliary (10-30%) and fecal (<10%).
Renal: 90-95% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <5% as unchanged drug and metabolites.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic